npj Regenerative Medicine Impact Factor: Beyond the Number in 2026

npj Regenerative Medicine Impact Factor: The Quick Answer

As of 2026, npj Regenerative Medicine’s impact factor sits between 6.5 and 7.0, depending on which source is checked and when its figures were last updated. Nature Portfolio’s own journal metrics page lists a 2025 Journal Impact Factor of 7.0, while the journal’s co-publisher, the Australian Regenerative Medicine Institute (ARMI), cites 6.5. Both figures are “official”; they simply reflect different update points in the metrics cycle.

That number answers one question well: how the journal performs as a whole. It does not reveal whether any single study published in that journal is valid, nor whether a clinic’s claim built on that study holds up. That distinction is the focus of this article.

Many people encounter this journal name for the first time when a regenerative medicine clinic cites it in marketing material, a consultation handout, or a linked study. Knowing the impact factor is a reasonable first step. Knowing what to do with it is the more important one.

Where the Number Actually Comes From: Comparing Official Sources

Impact factor is not a single fixed fact. Several indexing bodies and publishers report it, often on different update schedules, which is why reputable sources can legitimately disagree by a few tenths of a point. Rather than presenting one figure and ignoring the discrepancy, the clearest approach is to show where each number originates.

Nature Portfolio’s Official Metrics

Nature Portfolio’s journal metrics page reports the following figures for npj Regenerative Medicine:

• 2025 Journal Impact Factor: 7.0
• 5-year Journal Impact Factor: 8.1
• Immediacy index: 1.6
• Eigenfactor score: 0.00427
• Article Influence Score: 1.978

The page also lists a median submission-to-accept time of 216 days. That timeline is a practical marker of the journal’s peer-review process: papers are not accepted overnight, but typically go through months of review and revision before publication.

The Co-Publisher’s Figure (ARMI)

ARMI, the journal’s co-publishing partner based at Monash University, states on its own site that the npj Regenerative Medicine 2025 Impact Factor is 6.5.

This small gap offers a useful lesson. Two sources directly tied to the same journal can report slightly different numbers depending on when the snapshot was taken. Neither source is wrong; the difference simply shows that impact factor should be treated as an approximate signal rather than a precise, permanent score.

Independent Verification (OOIR / Web of Science)

Independent bibliometric aggregator OOIR reports an impact factor of 7.000, based on Web of Science 2025 data, which corroborates Nature Portfolio’s figure. OOIR also ranks the journal:

• #2 of 26 (Q1) in Cell & Tissue Engineering
• #12 of 89 (Q1) in Engineering, Biomedical

These rankings place the journal in the top quartile of its fields. They are helpful context for how it compares to peer publications, but they are not a quality seal for any individual article it publishes.

A Brief History of Volatility: Why the Number Has Swung So Much

npj Regenerative Medicine’s impact factor has moved considerably over a short period:

1. Debut: The journal’s first impact factor of 7.021 was announced in 2020.
2. Spike: It then rose sharply to 14.404, as early citations accumulated faster than the journal’s still-small number of published articles.
3. Settling: By the 2025 metrics cycle, it had stabilized in the 6.5 to 7.0 range.

The mechanism behind this pattern is straightforward. Impact factor divides citations by the number of articles published. When a journal is young and has published relatively few papers, the denominator is small, so a handful of highly cited articles can push the average up dramatically. As the journal grows and publishes more work, the average naturally moderates. This is a well-known statistical pattern among new journals, not a sign of declining quality.

Several facts reinforce the journal’s credibility:

• It has been publishing since 2016.
• It is part of the Nature Partner Journals series.
• It is co-published with ARMI (Australian Regenerative Medicine Institute, Monash University).
• It is fully open access, meaning any study it publishes is free to read.

That last point matters for patients. When a clinic cites an npj Regenerative Medicine article, the full study can be pulled up and checked independently, without a paywall standing in the way.

What Impact Factor Actually Measures, and What It Doesn’t

In plain terms, impact factor is a journal-level average of how often its articles are cited over a set period. It is not a score attached to any individual paper.

A 6.5 to 7.0 impact factor indicates that the journal, on average, is well cited and respected within its field. It says nothing about whether a particular study was well designed, whether its results were replicated, or whether its findings apply to a particular patient’s condition. A respected journal can still publish small early-phase studies, animal research, or laboratory work that is scientifically valuable but far from proof that a treatment works in people.

This creates a real risk. A legitimate, high-prestige journal name can be cited selectively to imply stronger support for a treatment than the underlying study actually provides. The journal’s reputation becomes a stand-in for evidence the study itself may not contain.

The Real Question Patients Should Be Asking

The question “Is this a good journal?” is reasonable, but it is not the most useful one. A better question is: “Does this specific study actually support this specific claim, for this specific condition?”

The International Society for Stem Cell Research (ISSCR) has built formal frameworks for exactly this kind of evaluation. Unlike journal-ranking sites, which are designed for researchers choosing where to publish and librarians managing collections, ISSCR’s guidance is aimed at helping patients and the public judge treatment claims.

The checklist below draws directly on that framework. It can be applied to any cited study, regardless of the journal it appears in.

The 5-Question Verification Checklist for Any Cited Study

This checklist is designed to be saved and reused. It works independently of a journal’s impact factor and should be applied to any study a clinic cites, whether it comes from npj Regenerative Medicine or any other publication.

Question 1: Is the Study Directly Relevant to This Specific Condition and Treatment?

An ISSCR task force framework, published in Cell Stem Cell, lists the direct relevance of the data to the specific disease and treatment in question as a core marker of evidence strength.

Practical tip: Compare the study’s details against the marketing claim. Check whether:

• The study population matches (humans versus animals, similar age range, similar severity)
• The injury or condition matches (for example, knee osteoarthritis versus a general cartilage model)
• The intervention matches (the same cell type, preparation, dose, and delivery method)

A study on the general topic area is not the same as a study on the specific treatment being offered.

Question 2: Has It Been Independently Replicated?

The same framework emphasizes publication by groups working independently of each other. When separate research teams reach the same result, the finding is far more trustworthy.

A single study, even a strong one in a respected journal, carries less weight than findings confirmed by multiple unrelated groups. Results that appear only once, or only from researchers with ties to the treatment provider, warrant extra caution.

Question 3: Was the Full Study, Methodology and Results, Actually Published?

The ISSCR framework calls for publication of results, methodologies, and conclusions. That means a complete peer-reviewed article, not:

• A conference abstract
• A press release
• A preliminary data summary or “teaser”
• A clinic’s internal outcomes report

ISSCR’s Patient Handbook also warns patients to be wary of clinics that rely on patient experiences rather than properly controlled studies. Testimonials can be sincere, but they cannot substitute for controlled research.

Question 4: Is the Study Indexed in MEDLINE?

The ISSCR framework includes inclusion in the MEDLINE database as a baseline peer-review and quality-control signal. MEDLINE is the U.S. National Library of Medicine’s curated index of biomedical literature.

Actionable step: Search PubMed using the study’s title or lead author’s name. Confirming whether a study is indexed takes under a minute.

Question 5: Is This One Treatment Being Marketed for Many Unrelated Conditions?

This is one of the clearest red flags in ISSCR guidance. When a single product or cell preparation is promoted for a long list of unrelated diseases, skepticism is warranted. As ISSCR explains, such conditions affect completely different tissues and involve very different disease processes, so it would be unusual for one identical cell preparation to be an effective treatment for all of them.

Readers should compare the scope of the clinic’s claim with the scope of the cited research. If the study examined one condition but the marketing applies it to many, the claim has stretched beyond its evidence.

How to Run This Audit in Practice

Applying the checklist is simpler than it might appear:

1. Locate the study. Ask the clinic for the exact title, authors, and journal, or a direct link.
2. Read the abstract. Because npj Regenerative Medicine is open access, the full article is available as well.
3. Work through the five questions in order. Note where the study meets each criterion and where it falls short.
4. Compare against the claim. Identify any gap between what the study found and what is being promised.

ISSCR’s Patient Handbook also recommends asking the clinic directly whether preclinical studies have been published, reviewed, and repeated by experts in the field. A provider confident in its evidence should welcome that question.

This audit applies equally to studies from journals with high, moderate, or low impact factors, because the checklist evaluates the study itself rather than where it was published.

Why This Verification Step Matters in Regenerative Medicine Decisions

Regenerative medicine is moving quickly. There are currently 224 clinical trials worldwide investigating stem cell therapies for osteoarthritis, and a major Phase III trial was announced in January 2026. With so much research underway, evidence quality varies widely even within the same broad treatment category. Some therapies have stronger support for certain conditions than others, and early findings do not always hold up in larger trials.

The ISSCR has stated plainly that for many conditions currently targeted by commercial stem cell and regenerative medicine clinics, there is not enough evidence of safety and effectiveness to justify routine commercial use. That caution holds even when a clinic cites a legitimate journal article.

None of this means regenerative treatments are illegitimate as a category. It means the evidence behind each specific recommendation deserves a close look. With more than 600,000 knee replacements performed annually in the United States, and studies suggesting a notable share of patients told they need total knee replacement may not actually require surgery, many people are actively weighing alternatives. Those decisions are best made with a clear view of what the evidence does and does not show.

How Unicorn Bioscience Approaches Evidence and Transparency

Unicorn Bioscience offers several cellular and regenerative therapy options, including stem cell therapy, PRP (platelet-rich plasma), BMAC (bone marrow aspiration concentrate), exosome therapy, hyaluronic acid injections, and peptide therapy, across its locations in Texas, Florida, and New York. The clinic encourages patients to apply exactly the kind of scrutiny described above to any study referenced during a consultation.

The clinic is also direct about regulatory status. It acknowledges that as of 2026, the FDA has not approved stem cell, PRP, or exosome products specifically for orthopedic conditions, while noting that its treatments are administered within the United States under FDA regulatory frameworks. For patients who might otherwise consider overseas medical tourism, that domestic setting offers a more accountable environment.

Treatment plans at Unicorn Bioscience are built around individual factors rather than a single product applied to every case. These factors include:

• Inflammation levels
• Patient age
• Injury type and location
• Current medications
• Personal health goals

Injections are delivered using ultrasound or X-ray guidance. The individualized approach aligns with the logic behind Question 5 of the checklist: matching a specific intervention to a specific condition, rather than presenting one preparation as a solution for unrelated problems.

Conclusion: Use the Number, Then Look Past It

npj Regenerative Medicine’s impact factor is reported between 6.5 and 7.0 across Nature Portfolio, ARMI, and independent aggregators such as OOIR as of the 2025 metrics cycle. It is a respected, open-access, top-quartile journal within its fields.

Impact factor is a useful signal about a journal’s overall standing. It is not a substitute for checking whether an individual study is directly relevant, independently replicated, fully published, and indexed in MEDLINE, or whether a clinic’s claim stays within the study’s actual scope.

The five-question checklist is worth keeping on hand as a permanent tool. New studies and new claims will continue to appear as the field develops, and the same questions will apply to every one of them.

Have a Study or Claim You Want to Verify?

Patients who have encountered a specific study, or a clinic claim built on one, can bring it to a consultation with Unicorn Bioscience’s clinical team for a transparent discussion of the underlying evidence and how it relates to their own condition.

Both virtual and in-person consultations are available across all eight locations: Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio, Boca Raton, and Manhattan. To schedule, call (737) 347-0446.

Unicorn Bioscience aims to provide evidence-based, transparent, and personalized guidance for patients exploring regenerative alternatives to surgery, with an emphasis on helping each patient understand what the research supports before making a decision.